Article
Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC).
Vascular medicine (London, England) - 1 Jun 2024
Ferrante Elisa A, Cudrici Cornelia D, Rashidi Mahmood, Fu Yi-Ping, Huffstutler Rebecca, Carney Katherine, Chen Marcus Y, St Hilaire Cynthia, Smith Kevin, Bagheri Hadi, Katz James D, Ferreira Carlos R, Gahl William A, Boehm Manfred, Brofferio Alessandra
Abstract excerpt
BACKGROUND: Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
